Global Mitral Valve Disease Market Size Likely to Grow at a CAGR of 8.5% By 2033

As per the current market research conducted by CMI Team, the global Mitral Valve Disease Market size is expected to record a CAGR of 8.5% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 2.9 billion. By 2032, the valuation is anticipated to reach USD 6.1 billion.

Mitral Valve Disease Market: Growth Factors and Dynamics

• Aging Population: The market experiences substantial growth due to the global demographic shift towards an aging population. The risk of developing mitral valve disease increases, creating a greater demand for diagnosis, treatment, and management solutions to address this prevalent cardiac condition.

• Increasing Prevalence: The rising incidence of mitral valve disease, encompassing mitral regurgitation and mitral stenosis, contributes significantly to market expansion. Aging populations and lifestyle changes play a pivotal role in the higher occurrence of this cardiac condition.

• Collaboration and Partnerships: Collaborations between healthcare providers, research institutions, and medical device companies drive advancements in the field of mitral valve disease. Collaborative efforts facilitate knowledge sharing, clinical trials, and the development of innovative treatment approaches, ultimately benefiting patients and fostering market growth.

• Technological Advancements: Continuous advancements in medical technologies, such as minimally invasive procedures, transcatheter mitral valve repair (TMVR), and innovative valve replacement devices, broaden treatment options and attract patients seeking advanced and less invasive interventions.

• Rising Healthcare Expenditure: The upward trend in healthcare spending, coupled with improved access to medical facilities and cutting-edge therapies, further supports the growing demand for effective treatments for mitral valve disease.

• Favourable Reimbursement Policies: Government initiatives and favourable reimbursement policies for cardiac treatments encourage patients to seek timely medical intervention, thereby positively impacting market growth.

• Growing Awareness: Heightened awareness campaigns focusing on mitral valve disease, early diagnosis initiatives, and educational programs drive increased patient screenings and encourage early interventions, contributing to market expansion.

• Lifestyle Changes: Modern lifestyle habits, including sedentary lifestyles, poor dietary choices, and smoking, contribute to the increasing prevalence of risk factors for mitral valve disease. Addressing lifestyle factors and promoting healthier habits become crucial in preventing and managing the condition, further driving the demand for medical interventions.

• Advancements in Diagnostic Technologies: The continuous advancements in diagnostic technologies, such as echocardiography, cardiac MRI, and 3D imaging, enable more accurate and early detection of mitral valve disease. Early diagnosis allows for timely interventions and improved patient outcomes, prompting healthcare providers to invest in these innovative diagnostic tools.

Mitral Valve Disease Market: Partnership and Acquisitions

• Micro Interventional Devices, Inc. and Lepu Medical Technology (Beijing) Co., Ltd.: In 2018, Micro Interventional Devices and Lepu Medical Technology collaborated to develop novel solutions for mitral valve disease treatment. The partnership aimed to combine Micro Interventional Devices’ expertise in minimally invasive technologies with Lepu Medical Technology’s market presence and distribution capabilities.

• Abbott Laboratories and Cibiem Inc.: In 2021, Abbott Laboratories entered into a partnership with Cibiem Inc. to explore innovative therapies for heart failure, including potential applications for mitral valve disease management. The collaboration sought to harness Cibiem’s expertise in cardiovascular medical devices and Abbott’s research capabilities to address unmet needs in the market.

• Boston Scientific Corporation acquires Symetis SA: In 2017, Boston Scientific acquired Symetis, a company specializing in transcatheter aortic valve replacement (TAVR) systems. The acquisition expanded Boston Scientific’s portfolio of valvular disease solutions, including potential synergies for mitral valve disease treatments.

• Edwards Lifesciences Corporation acquires CardiAQ Valve Technologies, Inc.: In 2017, Edwards Lifesciences acquired CardiAQ Valve Technologies, a company focused on developing transcatheter mitral valve replacement technology. The acquisition complemented Edwards Lifesciences’ existing mitral valve product line and reinforced its commitment to advancing mitral valve disease treatments.

Report Scope

Mitral Valve Disease Market: COVID-19 Analysis

The COVID-19 pandemic has had a significant impact on the Mitral Valve Disease Market, with the industry experiencing both positive and negative effects. Here are some of the key impacts:

• Delayed Diagnosis and Treatment: During the pandemic, many non-urgent medical appointments were postponed or cancelled, leading to delayed diagnosis and treatment of mitral valve disease cases. Patients might have hesitated to seek medical care due to fear of infection or overwhelmed healthcare systems.

• Disruptions in Medical Device Supply Chain: The global pandemic caused disruptions in the medical device supply chain, affecting the availability and distribution of cardiac implants, transcatheter mitral valve repair devices, and other essential equipment used in mitral valve disease management.

• Resumed Medical Services: As the pandemic subsides and healthcare facilities resume normal operations, the Mitral Valve Disease Market experiences increased patient flow, enabling timely diagnosis, treatment, and follow-up care.

• Telemedicine and Remote Monitoring: The pandemic accelerated the adoption of telemedicine and remote monitoring technologies. Integrating these solutions into post-pandemic care facilitates virtual consultations, remote patient monitoring, and timely medical advice for mitral valve disease patients.

• Innovation and Digital Solutions: The healthcare industry is embracing digital health solutions, such as remote patient monitoring devices and virtual healthcare platforms, which enhance patient engagement and enable personalized care for individuals with mitral valve disease.

• Focus on Preventive Care: The pandemic heightened awareness of health risks, leading to a renewed focus on preventive care. Healthcare providers promote lifestyle modifications, including healthy diet and exercise, to address risk factors for mitral valve disease and reduce disease burden.

In conclusion, the COVID-19 pandemic has had a mixed impact on the Mitral Valve Disease Market, with some challenges and opportunities arising from the pandemic. Manufacturers and retailers need to remain agile and adapt to the changing market conditions to overcome these challenges and capitalize on new growth opportunities.

List of the prominent players in the Mitral Valve Disease Market:

• Abbott Laboratories
• Medtronic plc
• Edwards Lifesciences Corporation
• Boston Scientific Corporation
• LivaNova PLC
• Micro Interventional Devices Inc.
• XELTIS AG
• Lepu Medical Technology (Beijing) Co. Ltd.
• CryoLife Inc.
• Colibri Heart Valve LLC
• Others

The Mitral Valve Disease Market is segmented as follows:

By Treatment Type

• Mitral Valve Repair
• Mitral Valve Replacement
• Cardiac Resynchronization Therapy
• Mitral Valve Therapeutics

By Indication

• Mitral Valve Stenosis
• Mitral Valve Prolapse
• Mitral Valve Regurgitation

By End User

• Hospitals
• Ambulatory Surgical Centres
• Others

By Region

North America

• The U.S.
• Canada
• Mexico

Europe

• France
• The UK
• Spain
• Germany
• Italy
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America